159 related articles for article (PubMed ID: 30745098)
1. Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.
Miyake Y; Itoh Y; Hatanaka A; Suzuma Y; Suzuki M; Kodama H; Arai Y; Suzuki T
Bioorg Med Chem; 2019 Mar; 27(6):1119-1129. PubMed ID: 30745098
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design and discovery of potent and selective KDM5 inhibitors.
Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
[TBL] [Abstract][Full Text] [Related]
3. Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors.
Jaikhan P; Buranrat B; Itoh Y; Chotitumnavee J; Kurohara T; Suzuki T
Bioorg Med Chem Lett; 2019 May; 29(10):1173-1176. PubMed ID: 30928196
[TBL] [Abstract][Full Text] [Related]
4. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.
Vinogradova M; Gehling VS; Gustafson A; Arora S; Tindell CA; Wilson C; Williamson KE; Guler GD; Gangurde P; Manieri W; Busby J; Flynn EM; Lan F; Kim HJ; Odate S; Cochran AG; Liu Y; Wongchenko M; Yang Y; Cheung TK; Maile TM; Lau T; Costa M; Hegde GV; Jackson E; Pitti R; Arnott D; Bailey C; Bellon S; Cummings RT; Albrecht BK; Harmange JC; Kiefer JR; Trojer P; Classon M
Nat Chem Biol; 2016 Jul; 12(7):531-8. PubMed ID: 27214401
[TBL] [Abstract][Full Text] [Related]
5. The KDM5 family of histone demethylases as targets in oncology drug discovery.
Rasmussen PB; Staller P
Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
[TBL] [Abstract][Full Text] [Related]
6. Identification of potent, selective KDM5 inhibitors.
Gehling VS; Bellon SF; Harmange JC; LeBlanc Y; Poy F; Odate S; Buker S; Lan F; Arora S; Williamson KE; Sandy P; Cummings RT; Bailey CM; Bergeron L; Mao W; Gustafson A; Liu Y; VanderPorten E; Audia JE; Trojer P; Albrecht BK
Bioorg Med Chem Lett; 2016 Sep; 26(17):4350-4. PubMed ID: 27476424
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
Horton JR; Engstrom A; Zoeller EL; Liu X; Shanks JR; Zhang X; Johns MA; Vertino PM; Fu H; Cheng X
J Biol Chem; 2016 Feb; 291(6):2631-46. PubMed ID: 26645689
[TBL] [Abstract][Full Text] [Related]
8. Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds.
Horton JR; Liu X; Gale M; Wu L; Shanks JR; Zhang X; Webber PJ; Bell JSK; Kales SC; Mott BT; Rai G; Jansen DJ; Henderson MJ; Urban DJ; Hall MD; Simeonov A; Maloney DJ; Johns MA; Fu H; Jadhav A; Vertino PM; Yan Q; Cheng X
Cell Chem Biol; 2016 Jul; 23(7):769-781. PubMed ID: 27427228
[TBL] [Abstract][Full Text] [Related]
9. Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.
Liang J; Zhang B; Labadie S; Ortwine DF; Vinogradova M; Kiefer JR; Gehling VS; Harmange JC; Cummings R; Lai T; Liao J; Zheng X; Liu Y; Gustafson A; Van der Porten E; Mao W; Liederer BM; Deshmukh G; Classon M; Trojer P; Dragovich PS; Murray L
Bioorg Med Chem Lett; 2016 Aug; 26(16):4036-41. PubMed ID: 27406798
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
Horton JR; Woodcock CB; Chen Q; Liu X; Zhang X; Shanks J; Rai G; Mott BT; Jansen DJ; Kales SC; Henderson MJ; Cyr M; Pohida K; Hu X; Shah P; Xu X; Jadhav A; Maloney DJ; Hall MD; Simeonov A; Fu H; Vertino PM; Cheng X
J Med Chem; 2018 Dec; 61(23):10588-10601. PubMed ID: 30392349
[TBL] [Abstract][Full Text] [Related]
11. Structural optimization of a lysine demethylase 5 inhibitor for improvement of its cellular activity.
Terao M; Yamashita Y; Takada Y; Itoh Y; Suzuki T
Bioorg Med Chem; 2024 Jan; 98():117579. PubMed ID: 38168630
[TBL] [Abstract][Full Text] [Related]
12. From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.
Liang J; Labadie S; Zhang B; Ortwine DF; Patel S; Vinogradova M; Kiefer JR; Mauer T; Gehling VS; Harmange JC; Cummings R; Lai T; Liao J; Zheng X; Liu Y; Gustafson A; Van der Porten E; Mao W; Liederer BM; Deshmukh G; An L; Ran Y; Classon M; Trojer P; Dragovich PS; Murray L
Bioorg Med Chem Lett; 2017 Jul; 27(13):2974-2981. PubMed ID: 28512031
[TBL] [Abstract][Full Text] [Related]
13. Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.
Labadie SS; Dragovich PS; Cummings RT; Deshmukh G; Gustafson A; Han N; Harmange JC; Kiefer JR; Li Y; Liang J; Liederer BM; Liu Y; Manieri W; Mao W; Murray L; Ortwine DF; Trojer P; VanderPorten E; Vinogradova M; Wen L
Bioorg Med Chem Lett; 2016 Sep; 26(18):4492-4496. PubMed ID: 27499454
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis and Characterization of Covalent KDM5 Inhibitors.
Vazquez-Rodriguez S; Wright M; Rogers CM; Cribbs AP; Velupillai S; Philpott M; Lee H; Dunford JE; Huber KVM; Robers MB; Vasta JD; Thezenas ML; Bonham S; Kessler B; Bennett J; Fedorov O; Raynaud F; Donovan A; Blagg J; Bavetsias V; Oppermann U; Bountra C; Kawamura A; Brennan PE
Angew Chem Int Ed Engl; 2019 Jan; 58(2):515-519. PubMed ID: 30431220
[TBL] [Abstract][Full Text] [Related]
15. KDM5 Lysine Demethylases in Pathogenesis, from Basic Science Discovery to the Clinic.
Zhang SM; Cao J; Yan Q
Adv Exp Med Biol; 2023; 1433():113-137. PubMed ID: 37751138
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological inhibition of KDM5A for cancer treatment.
Yang GJ; Wu J; Miao L; Zhu MH; Zhou QJ; Lu XJ; Lu JF; Leung CH; Ma DL; Chen J
Eur J Med Chem; 2021 Dec; 226():113855. PubMed ID: 34555614
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of KDM5A in human cancer.
Yang GJ; Zhu MH; Lu XJ; Liu YJ; Lu JF; Leung CH; Ma DL; Chen J
J Hematol Oncol; 2021 Feb; 14(1):30. PubMed ID: 33596982
[TBL] [Abstract][Full Text] [Related]
18. Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells.
Tumber A; Nuzzi A; Hookway ES; Hatch SB; Velupillai S; Johansson C; Kawamura A; Savitsky P; Yapp C; Szykowska A; Wu N; Bountra C; Strain-Damerell C; Burgess-Brown NA; Ruda GF; Fedorov O; Munro S; England KS; Nowak RP; Schofield CJ; La Thangue NB; Pawlyn C; Davies F; Morgan G; Athanasou N; Müller S; Oppermann U; Brennan PE
Cell Chem Biol; 2017 Mar; 24(3):371-380. PubMed ID: 28262558
[TBL] [Abstract][Full Text] [Related]
19. KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.
Heward J; Konali L; D'Avola A; Close K; Yeomans A; Philpott M; Dunford J; Rahim T; Al Seraihi AF; Wang J; Korfi K; Araf S; Iqbal S; Bewicke-Copley F; Kumar E; Barisic D; Calaminici M; Clear A; Gribben J; Johnson P; Neve R; Cutillas P; Okosun J; Oppermann U; Melnick A; Packham G; Fitzgibbon J
Blood; 2021 Aug; 138(5):370-381. PubMed ID: 33786580
[TBL] [Abstract][Full Text] [Related]
20. Hit to lead optimization of pyrazolo[1,5-a]pyrimidines as B-Raf kinase inhibitors.
Gopalsamy A; Ciszewski G; Shi M; Berger D; Hu Y; Lee F; Feldberg L; Frommer E; Kim S; Collins K; Wojciechowicz D; Mallon R
Bioorg Med Chem Lett; 2009 Dec; 19(24):6890-2. PubMed ID: 19884006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
